Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
003 APL-130277 OFF episodes associated with Parkinson’s disease Registration (U.S.)
004 Dasotraline Attention deficit hyperactivity disorder (ADHD), adult and pediatric Registration (U.S.)
005 Dasotraline Binge eating disorder (BED), adult Registration (U.S.)
006 SEP-363856 Schizophrenia Phase 3
007 SEP-363856 Parkinson’s disease psychosis Phase 2
008 SEP-4199 Bipolar depression Phase 2
009 SB623 Chronic stroke Phase 2
013 DSP-3905 Neuropathic pain Phase 1
014 DSP-6745 Parkinson's disease psychosis Phase 1
015 SEP-378608 Bipolar disorder Phase 1
015 SEP-378614 Treatment resistant depression Phase 1
015 SEP-380135 Agitation in Alzheimer's disease Phase 1